Revascularisation, periprocedural events and survival – and the survival of the randomised controlled trial

EuroIntervention 2023;18:1218-1219. DOI: 10.4244/EIJ-E-23-00004

Alexandra Lansky
Alexandra J. Lansky1, MD; Yousif Ahmad1, MD, PhD
1. Division of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
The Surgical Treatment for Ischemic Heart Failure (STICH) randomised controlled trial (RCT) found that serious postoperative complications occurred in nearly one-quarter of patients who underwent coronary artery bypass grafting (CABG) for ischaemic cardiomyopathy and that these events were associated with 30-day mortality1. There was a clear gradation demonstrated between the number of complications that occurred and a patient’s survival: patients with no complications had <1% mortality, those with 1 complication had 7% mortality, those with 2 had 31% mortality, those with 3 had 33% mortality, and those with ≥4 complications had 59% mortality at 30 days. While there are published data on the occurrence and prognostic ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Periprocedural adverse events after revascularisation: the importance of getting off to a good start

Latest news